Big money showing panels discussing a dozen countries banning junk food from snap profits.
PFizer has secured a $10 billion deal to acquire high-growth drug maker metsera, ending a bitter battle with Danish rival Norto Nordisk.
Metshera accepted a sweetened offer from PFizer late on Friday, revealing the risk that Antitrust in Novo’s bid was previously called for, according to opponents. Danish Offesity-Drug Giant Hisson said on Saturday it would withdraw from the competition.
The win gives PFIZER FFEOIZER in the lucrative Offessity-Drug market, even if Metsera’s treatment remains unapproved. The loss marks a setback for NOVO as it tries to cut back on US soil Eli Lilly.
Wegovy, Ozempic: Barriers to accessing these weight loss drugs
PFizer has secured a 10 billion deal to acquire drug developer Offera, beating Danish rival Norvo Nordisk in a fierce battle. (Kena Bena Betancur/ViewPress/Getty Images)
In a statement, Nordisk Nordisk confirmed that it was withdrawing from its trial acquisition after several offers, saying that it judged the price and presentation of the fight to be more detailed.
Novo Novo raised twice its metsera bid – first to $ 10 billion, and then almost the same amount with a higher payment and small performance bonuses. But after Metsera pointed to the risk of killing antitrust and dependent on Pfizer’s contoffer, Novo said it would withdraw and not raise its offer. In addition, it revealed financial discipline and the share price.
Inths of Health Inschares Pursuing Back to Medicare Invanced by 2026
“We believe that the structure of our potential agreement complies with antitrust laws,” Nova said in a statement. “Following a competitive process and after careful consideration, Nord Nordisk will not increase its offer to acquire Metsera, consistent with its commitment to financial discipline and share price.”
Injection pens for WEgovy weight loss treatment, manufactured by Novo Nordisk A/S, on display during a press conference in Mumbai, India, on June 24, 2025. (Dhiraj Singh/Bloomberg via Getty Images/Getty Images)
Nova said it will continue to explore business development opportunities and acquisitions that meet its return and capital allocation criteria.
The Mets, in their statement Friday, said Novava’s proposal presented “higher legal and regulatory risks” compared to the proposed merger with the Federal Trade Commission to discuss potential concerns. The regulator sent a letter earlier in the week to the church with Novo and Metsca, warning that their proposed agreement risks violating antitrust laws.
Pfizer said it is pleased to have reached a revised agreement with Metsca and expects to close the merger shortly after the Nov. 13 of the rebels.
Prescription weight loss medications ozempic, Vitoaza and Wegovy. (Michael Siluk / UCG / Urfery Images Group via Getty Images / Getty Images)
Bernstein Analyst Courtney Breen said that the price of $ 10 billion is rested on the future healthy performance, estimating that pfizer will need to generate about $ 11 billion in current costs from 2040 – almost the current of Metsera’s Current.
He pointed out the increasing inflation surrounding the long-term prices of GLP-1, which can reduce margins.
Find FOX business on the go by clicking here
Metsera’s board recommended that shareholders approve Pfizer’s revised offer. The biotech is currently operating at a loss and analysts expect more losses as its drugs continue to be developed.
Reuters contributed to this report.
